Acura Pharmaceuticals (ACUR): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACUR Stock Summary
- ACUR has a higher market value than merely 1.86% of US stocks; more precisely, its current market capitalization is $7,957,680.
- Acura Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 5.23% of US listed stocks.
- ACUR's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 6.36% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Acura Pharmaceuticals Inc are MUX, MESO, FAMI, CPLG, and RVI.
- ACUR's SEC filings can be seen here. And to visit Acura Pharmaceuticals Inc's official web site, go to www.acurapharm.com.
ACUR Stock Price Chart Interactive Chart >
ACUR Price/Volume Stats
| Current price | $0.36 | 52-week high | $0.50 |
| Prev. close | $0.38 | 52-week low | $0.15 |
| Day low | $0.36 | Volume | 2,400 |
| Day high | $0.37 | Avg. volume | 14,555 |
| 50-day MA | $0.37 | Dividend yield | N/A |
| 200-day MA | $0.30 | Market Cap | 7.99M |
Acura Pharmaceuticals (ACUR) Company Bio
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was founded in 1935 and is based in Palatine, Illinois.
Latest ACUR News From Around the Web
Below are the latest news stories about Acura Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACUR as an investment opportunity.
Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Financial ResultsPALATINE, Ill., March 31, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and twelve months ended December 31, 2020. The Company reported an operating loss of $0.1 million for the fourth quarter 2020 compared to an operating income of $0.3 million for the same period in 2019. For the twelve months ended December 31, 2020, the Company reported an operating loss of $0.8 million compared to an operating loss of $0.7 million for the same period in 2019. Included in expenses for the results for 2020 was a one-time charge of $668 thousand to recognize an impai... |
Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03Amendment Extends NDA Acceptance Date and Expands AgreementPALATINE, Ill., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC (“AD Pharma”) to extend the FDA Acceptance Date for LTX-03 (“NDA Acceptance Date”), expand the product licenses, and revise the license payment schedule. Acura’s LIMITx™ technology, when applied to any pharmaceutical product, is designed to mitigate the adverse consequences associated with the overdose of tablets. The amended Agreement extends the NDA Acceptance Date to July 31, 2021, expands AD Pharma’s license to the LIMITx™ patents to LTX-02 (... |
ACUR Price Returns
| 1-mo | -1.37% |
| 3-mo | 9.09% |
| 6-mo | 53.85% |
| 1-year | 9.09% |
| 3-year | -7.69% |
| 5-year | -81.15% |
| YTD | 71.43% |
| 2020 | -8.70% |
| 2019 | 100.17% |
| 2018 | -71.55% |
| 2017 | -47.55% |
| 2016 | -69.20% |
Loading social stream, please wait...